SUN-777 CALIBRATE-PEDS: A Phase 2/3, Multicenter, Single-Arm, Open-Label Study Evaluating the Pharmacokinetics, Efficacy, and Safety of Encaleret in Pediatric Participants with Autosomal Dominant Hypocalcemia Type1
Bibliographic record
Abstract
Abstract Disclosure: P.J. Tebben: Consultancy fees and research funding from Calcilytix. T. Alexander: Steering Committee Member Calcilytix Therapeutics Inc. Honoraria Ultragenyx. S. Mora: Consultancy fees from Calcilytix. R. Padidela: Consultancy fees from Calcilytix. M. Roberts: Employee of BridgeBio and own company stock. D. Li: Employee of BridgeBio and own company stock. S. Adler: Employee of BridgeBio and own company stock. R.I. Gafni: The NIDCR receives research funding from Calcilytix Therapeutics, Steering committee member (unpaid) for adult and pediatric encaleret studies, Medical advisory board (unpaid) of The Hypoparathyroidism Association. Objectives: Autosomal dominant hypocalcemia type 1 (ADH1), caused by gain-of-function variants in the calcium-sensing receptor gene, is characterized by low/inappropriately normal parathyroid hormone (PTH), hypocalcemia, and hypercalciuria. Standard-of-care (SoC) treatment (calcium and active vitamin D) worsens hypercalciuria, increasing renal morbidity. Encaleret, a negative allosteric modulator of the calcium-sensing receptor, is under investigation as a potential ADH1 treatment. In a Phase 2b study [NCT04581629] in 13 adults with ADH1, encaleret led to sustained normalization in PTH, albumin-corrected calcium (cCa), phosphorus, magnesium and 24-hr urine calcium (UCa) excretion over 24 weeks, without serious adverse events reported. A Phase 3 study [NCT05680818, CALIBRATE] in adults with ADH1 is ongoing. CALIBRATE-PEDS is a Phase 2/3 study evaluating pharmacokinetics (PK), efficacy, and safety of encaleret in children with ADH1. Methods: Approximately 28 children (birth-18y) will be enrolled in 4 age cohorts sequentially, starting with the oldest cohort (12-18y). After 3-6 months of stable SoC/PTH treatment, eligible participants will enter Period 1, an inpatient stay lasting up to 6 days, for PK sampling and individualized dose titration. Period 2 follows, during which encaleret doses will be optimized to maintain target cCa while minimizing UCa over 20 outpatient weeks. Period 3 is a 4-week dose maintenance period, when the dose is intended to be fixed. Participants may then continue into a long-term extension period for safety monitoring and continued access to encaleret. PK data from Period 1 will be used to refine population-based PK modeling and inform dosage in younger cohorts. Results: The primary endpoint is the composite endpoint of a) cCa within 8.4 to 10.4 mg/dL in participants aged ≥ 1 year, and within 8.2 to 11.4 mg/dL in participants aged < 1 year and b) UCa <4 mg/kg/d in toilet-trained participants or spot ratio of UCa/UCr within the age-specific reference range in non-toilet-trained participants. Participants meeting both criteria at the end of Period 3 will be considered responders. Key secondary endpoints include safety and tolerability, mineral homeostasis, renal ultrasound, bone density, and self-reported outcomes. The statistical analyses will be descriptive; no statistical testing is planned. Conclusions: CALIBRATE-PEDS is the first pediatric study of encaleret. It is under development and is expected to be initiated globally in 2025. Presentation: Sunday, July 13, 2025
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.002 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.001 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.000 |
| Research integrity | 0.001 | 0.003 |
| Insufficient payload (model declined to judge) | 0.008 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".